

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human Transgelin/TAGLN in ELISAs and Western blots.
Source	Monoclonal Mouse IgG ₁ Clone # 859112
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	<i>E. coli</i> -derived recombinant human Transgelin/TAGLN Ala2-Ser201 Accession # Q01995
Conjugate	Alexa Fluor 488 Excitation Wavelength: 488 nm Emission Wavelength: 515-545 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

Western Blot	Optimal dilution of this antibody should be experimentally determined.
Immunocytochemistry	Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

TAGLN (Transgelin; also 22 kDa Actin-binding protein, WS3-10 and Smooth muscle protein 22 alpha) is a 22-24 kDa cytosolic member of the calponin (calcium-binding and calmodulin-binding troponin T-like protein) family of molecules. It is expressed in both visceral and vascular smooth muscle, fibroblasts, cardiac myocytes, and potentially in breast duct plus prostate epithelium. TAGLN is associated with the actin stress fibers and appears to both suppress MMP-9 production, and downmodulate Ca⁺⁺-independent smooth muscle contraction. Human TAGLN is 201 amino acids (aa) in length. It contains one CH/calponin homology domain (aa 24-137), and an actin-binding calponin-like repeat/CLIK (aa 175-200). There is one utilized phosphorylation site at Tyr193, plus two utilized acetylation sites in the N-terminus. Three potential isoform variants are reported, one that shows an alternative start site at Met111, a second that contains a new start site 10 aa upstream of the standard site, and a third that possesses a 58 aa substitution for aa 97-201. Full-length human and mouse TAGLN share 97% aa sequence identity.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.